Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | UGCG | Q16739 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27717097 | 0.92 | RORC (0.50) | SMOCYP2C9RORCRAB9AMAPT | |
| SCHEMBL2095046 | 0.91 | RAB9A (0.51) | SMOCYP2C9RORCRAB9AMAPT | |
| SCHEMBL10187707 | 0.90 | MEN1 (0.44) | RAB9AMAPTMAPK1LMNASMN1; SMN2 | |
| SCHEMBL27717099 | 0.86 | MEN1 (0.53) | RAB9AMAPTMAPK1LMNASMN1; SMN2 | |
| SCHEMBL2094733 | 0.84 | PTGS1 (0.41) | CYP2C9MAPTMAPK1LMNAKDR | |
| SCHEMBL2092485 | 0.82 | TRPV1 (0.43) | CYP2C9RAB9AMAPK1LMNASMN1; SMN2 | |
| SCHEMBL10187725 | 0.81 | RAB9A (0.47) | CYP2C9RAB9AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL2091612 | 0.81 | STIM1 (0.55) | CYP2C9RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL2096523 | 0.81 | NPC1 (0.50) | CYP2C9RAB9AMAPTMAPK1LMNA | |
| SCHEMBL2093588 | 0.81 | LMNA (0.43) | CYP2C9RAB9AMAPTMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524756-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524756-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130142831-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130142831-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8314134-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314134-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8163777-B2 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163777-B2 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100311787-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311787-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7709518-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709518-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20070254912-A1 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070254912-A1 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070249661-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249661-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007112093-A2 | BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254912-A1 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | NLRP3, CXCR1, CXCR2 | SMO 4413/4885CYP2C9 130/4885RORC 98/4885 |
| US-20100311787-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | SMO 4576/4885CYP2C9 621/4885RORC 102/4885 |
| US-20070249661-A1 | Compounds for inflammation and immune-related uses | CXCR2, CXCL8, CCR9 | SMO 4576/4885CYP2C9 621/4885RORC 102/4885 |
| US-20130142831-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | SMO 4576/4885CYP2C9 621/4885RORC 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.